DataMeds AI (MEDS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$8.0M

Revenue (quarter)

$1.8M

Revenue growth (year over year)

−77.15%

Gross profit (trailing twelve months)

−$7.3M

Gross margin

−90.64%

Net income (trailing twelve months)

−$88.3M

Net income (quarter)

−$18.4M

Net income growth (year over year)

−175.21%

Net margin

−1100.30%

Return on equity

—

EPS (trailing twelve months)

−$48.30

Book value per share

−$6.88

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

159.54%

Payout ratio

—

Dividend yield

—

Company profile

DataMEDS AI Inc is a healthcare technology and pharmaceutical logistics company. The group simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a single, integrated platform for pharmacies, wholesale distribution, and a fulfillment network focused on Independent Pharmacies and Specialty Lite medications.

• Is DataMeds AI (MEDS) profitable?

  No. DataMeds AI reported a net loss of $88.3M over the trailing twelve months.

• How much revenue does DataMeds AI (MEDS) make?

  DataMeds AI generated $8.0M in revenue over the trailing twelve months, down 77.15% year over year.

• How do I buy stock in DataMeds AI (MEDS)?

  MEDS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.